HP is a 24 y/o male that presents to your clinic with 2 to 3 lesions of mild impetigo. What is the most effective treatment for HP?

Hormone replacement therapy (HRT) is used to manage menopausal symptoms such as hot flashes, vaginal dryness, and sleep disturbances by replacing declining estrogen levels. In women with an intact uterus, estrogen therapy must be carefully balanced with progestin to protect the endometrial lining. Unopposed estrogen stimulates endometrial proliferation, which increases the risk of abnormal hyperplasia and malignancy. Understanding this balance is essential for safe long-term hormone therapy.

Rationale:
A. Reduced risk for colon cancer is not the primary reason for adding progestin to hormone therapy. While some studies suggest combined hormone therapy may have minor effects on colorectal cancer risk, this is not the clinical rationale for dual therapy. The key concern in prescribing HRT is endometrial safety, not cancer prevention in the colon.

B. Combined hormone therapy does not reduce the risk of venous thromboembolism (VTE). In fact, both estrogen-only and combined therapies can increase thrombotic risk depending on route and patient factors. The addition of progestin is specifically for endometrial protection, not for reducing clotting risk.

C. Unopposed estrogen significantly increases the risk of endometrial hyperplasia and endometrial cancer in women with an intact uterus. Therefore, a progestin must be added to counteract estrogen’s proliferative effect on the endometrial lining. This protective mechanism is the primary reason for prescribing combination therapy in hormone replacement regimens.

D. While combination therapy may help relieve menopausal vasomotor symptoms such as hot flashes, this is not the reason progestin is required. Hormone replacement therapy is primarily structured to balance estrogen’s effects on the endometrium rather than to enhance symptom relief. Symptom control is a benefit, but not the safety indication for adding progestin.

Plaque psoriasis is a chronic inflammatory skin disorder characterized by well-demarcated erythematous plaques with silvery scaling, resulting from rapid keratinocyte turnover and immune-mediated inflammation. Initial treatment is typically based on disease severity, with mild to moderate cases managed using topical therapies that reduce inflammation and control plaque formation. Corticosteroids are the mainstay of first-line therapy due to their strong anti-inflammatory effects and rapid symptom control when used appropriately.

Rationale:
A. Anthralin (Dritho-Creme) is effective for psoriasis by slowing keratinocyte proliferation, but it is not commonly used as initial therapy due to its irritant properties, staining of skin and clothing, and need for careful application. It is generally reserved for more resistant plaques or as an adjunct therapy rather than first-line treatment.

B. Pimecrolimus (Elidel) is primarily indicated for atopic dermatitis, especially in sensitive areas such as the face or intertriginous regions. It is not considered a first-line treatment for plaque psoriasis because it has limited efficacy on thick, scaly plaques found in typical psoriatic lesions.

C. Burow’s solution (aluminum acetate) wet soaks are used for soothing inflamed or weeping skin conditions, such as acute dermatitis or minor skin infections. While they may provide symptomatic relief, they do not address the underlying immune-mediated inflammation of plaque psoriasis and are not effective as primary treatment.

D. Triamcinolone 0.1% (Kenalog) is an appropriate initial treatment for plaque psoriasis because it effectively reduces inflammation, erythema, and scaling. Intermittent “pulse” therapy helps minimize side effects such as skin atrophy while maintaining disease control. Topical corticosteroids are considered first-line therapy for localized mild to moderate plaque psoriasis due to their efficacy and rapid symptom relief.